Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Time to antimicrobial therapy in septic shock patients treated with an early goal‐directed resuscitation protocol: A post‐hoc analysis of the ARISE trial.

Tytuł:
Time to antimicrobial therapy in septic shock patients treated with an early goal‐directed resuscitation protocol: A post‐hoc analysis of the ARISE trial.
Autorzy:
Bulle, Esther B
Peake, Sandra L
Finnis, Mark
Bellomo, Rinaldo
Delaney, Anthony
Peake, S.
Delaney, A.
Bellomo, R.
Cameron, P. A.
Higgins, A. M.
Holdgate, A.
Howe, B.D.
Webb, S.A.R.
Williams, P.
Cooper, D. J.
Cross, A.
Gomersall, C.
Graham, C.
Higgins, A.M.
Jacobs, I.
Temat:
STATISTICS
HOSPITAL emergency services
CONFIDENCE intervals
DESCRIPTIVE statistics
RESUSCITATION
DATA analysis
ODDS ratio
SEPTIC shock
ANTIBIOTICS
Źródło:
Emergency Medicine Australasia; Jun2021, Vol. 33 Issue 3, p409-417, 9p
Czasopismo naukowe
Objective: Intravenous antimicrobial therapy within 1 h of the diagnosis of septic shock is recommended in international sepsis guidelines. We aimed to evaluate the association between antimicrobial timing and mortality in patients presenting to the ED with septic shock. Methods: Post‐hoc analysis of 1587 adult participants enrolled in the Australasian Resuscitation in Sepsis Evaluation (ARISE) multicentre trial of early goal‐directed therapy for whom the time of initial antimicrobial therapy was recorded. We compared participants who had initiation of antimicrobials within the first hour (early) or later (delayed) of ED presentation. A propensity score model using inverse probability of treatment weighting was constructed to account for confounding baseline covariates. The primary outcome was 90‐day mortality. Results: The median (interquartile range) time to initiating antimicrobials was 69 (39–112) min with 712 (44.9%) participants receiving the first dose within the first hour of ED presentation. Compared with delayed therapy, early administration was associated with increased baseline illness severity score and greater intensity of resuscitation pre‐randomisation (fluid volumes, vasopressors, invasive ventilation). All‐cause 90‐day mortality was also higher; 22.6% versus 15.5%; unadjusted odds ratio (OR) 1.58 (95% confidence interval [CI] 1.16–2.15), P = 0.004. After inverse probability of treatment weighting, the mortality difference was non‐significant; OR 1.30 (95% CI 0.95–1.76), P = 0.1. Live discharge rates from ICU (OR 0.81, 95% CI 0.72–0.91; P = 0.80) and hospital (OR 0.93, 95% CI 0.82–1.06; P = 0.29) were also not different between groups. Conclusion: In this post‐hoc analysis of the ARISE trial, early antimicrobial therapy was associated with increased illness severity, but 90‐day adjusted mortality was not reduced. [ABSTRACT FROM AUTHOR]
Copyright of Emergency Medicine Australasia is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies